mPEG-PLA from PolySciTech used in development of quantitative microscopy assay for particle circulation time

One of the key parameters for nanoparticle-based drug delivery is how long the particles can remain in the blood-stream before being removed by the bodily systems. The time it takes for roughly half the particles to be cleared by the liver, kidneys, or other mechanisms is considered the particle half-life and is a critical parameter in defining appropriate dosages of the particle materials. Recently, Researchers at Yale University used mPEG-PLA (AK054) from PolySciTech (www.polyscitech.com) to create test nanoparticles for work on their development of a microscopic-based technique which can quickly and efficiently determine particle half-life. This research holds promise for further development of nanotherapy based medicines. Read more: Bracaglia, Laura G., Alexandra S. Piotrowski-Daspit, Chun-Yu Lin, Zoe M. Moscato, Yongheng Wang, Gregory T. Tietjen, and W. Mark Saltzman. "High-throughput quantitative microscopy-based half-life measurements of intravenously injected agents." Proceedings of the National Academy of Sciences (2020). https://www.pnas.org/content/early/2020/01/30/1915450117.short

“Accurate analysis of blood concentration and circulation half-life is an important consideration for any intravenously administered agent in preclinical development or for therapeutic application. However, the currently available tools to measure these parameters are laborious, expensive, and inefficient for handling multiple samples from complex multivariable experiments. Here we describe a robust high-throughput quantitative microscopy-based method to measure the blood concentration and circulation half-life of any fluorescently labeled agent using only a small (2 µL) amount of blood volume, enabling additional end-point measurements to be assessed in the same subject. To validate this method, we demonstrate its use to measure the circulation half-life in mice of two types of fluorescently labeled polymeric nanoparticles of different sizes and surface chemistries and of a much smaller fluorescently labeled monoclonal antibody. Furthermore, we demonstrate the improved accuracy of this method compared to previously described methods.”

--> Save-the-date: Akina, Inc's third annual Biotech-Pharma-Cancer-Research (BPCR) conference is August 26 at Kurz Purdue Technology Center (KPTC) (http://bpcrconference.com/).